Hugh Calkins, MD A. John Camm, MD Elaine M. Hylek, MD, MPH Peter R. Kowey, MD

Release date: June 22, 2012
Expiration date: June 30, 2013
Estimated time to complete activity: 1.25 hours
Course viewing requirements:
PC: Internet Explorer (v6 or greater) or Firefox - MAC: Safari or Firefox

Jointly sponsored by Postgraduate Institute for Medicine ( and Medtelligence™.

This activity is supported by an educational grant from Sanofi US.

This program is not part of the Heart Rhythm 2012 Official Scientific Sessions as planned by the Heart Rhythm Society Scientific Sessions Program Committee. This activity is neither sponsored nor endorsed by the Heart Rhythm Society.

Target Audience
This activity has been designed to meet the educational needs of Electrophysiologists, EP Fellows and EP Lab Staff, Nurses, Nurse Practitioners, Physician Assistants, and other allied health professionals involved in the management of patients with cardiac arrhythmias.

Program Overview
This online activity is based on AF Spotlight: Changing the Paradigm in Atrial Fibrillation Management: You Be the Judge™ held on May 9, 2012 at the Heart Rhythm Society’s 33rd Annual Scientific Sessions. Selected faculty presentations (audio and slides) include Pharmacotherapy and Interventions for Rhythm Control in AF, Stroke Prevention in AF, and Monitoring AF to Optimize Outcomes.

Learning Objectives
After completing this activity, the participant should be better able to:
• Assess the potential of new and emerging therapeutic approaches to manage thromboembolic risk associated with thromboembolism and AF
• Describe the potential benefits and risks reported by recent large-scale randomized clinical trials of antiarrhythmic agents for rhythm control treatment of AF
• Apply the new ACC/AHA/HRS and ESC guidelines for management of patients with AF for stroke prevention, and conversion and maintenance of sinus rhythm

Hugh Calkins, MD, is the Nicholas J. Fortuin, MD Professor of Cardiology and Professor of Medicine at the Johns Hopkins University School of Medicine in Baltimore, Maryland. He is also the Director of the Clinical Electrophysiology Laboratory, the Arrhythmia Service, and the Atrial Fibrillation Center at the Johns Hopkins Hospital. Dr. Calkins earned a medical degree from Harvard Medical School and completed his residency in internal medicine at the Massachusetts General Hospital. He received cardiology fellowship training at Johns Hopkins and trained in electrophysiology at Johns Hopkins and at the University of Michigan. Dr. Calkins has published numerous manuscripts and book chapters and lectured extensively throughout the world. The focus of his research efforts have been on atrial fibrillation, catheter ablation, syncope, and arrhythmogenic right ventricular dysplasia. Dr. Calkins sits on the editorial boards of the Journal of the American College of Cardiology, Heart Rhythm, the Journal of Interventional Electrophysiology, the Journal of Cardiovascular Electrophysiology, and Circulation Arrhythmia and Electrophysiology. He currently serves as first Vice President of the Heart Rhythm Society.

A. John Camm, MD, is a Professor of Clinical Cardiology and Chairman of the Department of Cardiac and Vascular Sciences at St George’s University of London, United Kingdom. Dr. Camm graduated from Guy’s Hospital, London and pursued a career in Cardiology at St. Bartholomew’s Hospital. In 1986, he moved to the British Heart Foundation Chair of Clinical Cardiology at St. George’s Hospital. He is the President of the Arrhythmia Alliance; a trustee of the Atrial Fibrillation Association, the Drug Safety Research Unit, the American College of Cardiology, and the Interventional Cardiac Pacing and Electrophysiology Society; and Editor of Europace, the only European Journal devoted to cardiac electrophysiology and arrhythmology. Dr. Camm is also Editor of the European Society of Cardiology Textbook on Cardiovascular Medicine, Evidence Based Cardiology and Electrophysiology of the Heart. He is particularly interested in clinical cardiac electrophysiology, cardiac arrhythmias, and implantable devices for rhythm control. A worldwide renowned clinical trialist, Dr. Camm has held or holds memberships in 30 multicentre study committees and has given over 1000 lectures to international audiences and written more than 1000 peer review papers, more than 500 book chapters, and over 30 books.

Elaine M. Hylek, MD, MPH, is an Associate Professor of Medicine at Boston University School of Medicine and Director of the Thrombosis Clinic and Anticoagulation Service at Boston University Medical Center in Boston, Massachusetts. Dr. Hylek earned her medical degree from the University of Pittsburgh School of Medicine and completed her residency at Massachusetts General Hospital and fellowships at Massachusetts General Hospital and Harvard Medical School. She earned her MPH in Quantitative Methods from Harvard University School of Public Health. Her clinical research interests include cardiovascular disease, atrial fibrillation, thrombotic diseases, anticoagulation, diabetes, hypertension, stroke prevention, and quality improvement. Dr. Hylek has been published in numerous peer-reviewed journals, including Chest, New England Journal of Medicine, Circulation, JAMA, Journal of Thrombosis and Haemostasis, and Stroke. She is currently a Section Editor for Thrombosis and Haemostasis. Dr. Hylek maintains an active practice in internal medicine at the Yawkey Ambulatory Care Center at Boston Medical Center.

Peter R. Kowey, MD, is Chief of the Division of Cardiovascular Diseases at the Lankenau Hospital Main Line Health System, President of the Main Line Health Heart Center, and the William Wikoff Smith Chair in Cardiovascular Research. He is also Professor of Medicine and Clinical Pharmacology at Jefferson Medical College in Philadelphia, Pennsylvania. Dr. Kowey earned his medical degree at the University of Pennsylvania School of Medicine. He completed his residency training in internal medicine at Penn State University and was a Fellow in cardiovascular medicine and research at the Harvard University School of Public Health, the Peter Bent Brigham Hospital, and the West Roxbury VA Hospital. Dr. Kowey’s principal area of interest is cardiac rhythm disturbances. He has been the recipient of over 150 grants, authored or co-authored numerous papers and scientific reports, and is the co-editor of 3 textbooks regarding cardiac arrhythmia. His group has participated in a large number of pivotal clinical trials, many directed by Dr. Kowey. A referee for manuscript review for 25 journals, Dr. Kowey sits on the editorial boards of the Heart Rhythm Journal and the Journal of Cardiovascular Electrophysiology. Dr. Kowey published his first medical mystery novel, LETHAL RHYTHM, in November of 2010 and the sequel, DEADLY RHYTHM, is in its final preparation.

Physician Continuing Education
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine and Medtelligence, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Hugh Calkins, MD: Consulting Fees: Biosense Webster, Inc., Sanofi US

A. John Camm, MD:
Royalty: Oxford University Press, Elsevier; Consulting Fees: Adolor, Bayer HealthCare, Boehringer Ingelheim, BIOTRONIK, Boston Scientific Corporation, Bristol-Myers Squibb, CV Therapeutics (Gilead), Daiichi Sankyo Co., Ltd., Johnson & Johnson, Medtronic, Inc., Menarini, Merck & Co., Inc., Movetis (Shire), Novartis, Pfizer Inc., Sanofi, SERVIER, St. Jude Medical, Inc., Takeda Pharmaceutical Company Limited, Xention; Fees for Non-CME/CE Services: Sanofi; Contracted Research: Bristol-Myers Squibb, Daiichi Sankyo Co., Ltd., Sanofi, SERVIER

Elaine Hylek, MD, MPH:
Consulting Fees: Bayer HealthCare Pharmaceuticals Inc., Boehringer Ingelheim, Bristol- Myers Squibb, Daiichi Sankyo Co., Ltd., Johnson & Johnson, Merck & Co., Inc., Pfizer Inc.; Contracted Research: Bristol-Myers Squibb, Janssen Pharmaceuticals, Inc. (Ortho-McNeil)

Peter R. Kowey, MD: Consulting Fees: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Forest Pharmaceuticals, Inc., GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Sanofi US; Fees for Non-CME/CE Services: Boehringer Ingelheim, Johnson & Johnson, Sanofi US; Ownership Interest: CardioNet

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, Jan Schultz, RN, MSN, CCMEP, and Patricia Staples, MSN, NP-C, CCRN hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Medtelligence, LLC: Ben Caref, PhD, and Pamela Clark hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period June 22, 2012 through June 30, 2013, participants must read the learning objectives and faculty disclosures and study the educational activity. PIM supports Green CME by offering your Request for Credit online. If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation on On the navigation menu under course links, click on “Find Evaluation/Post-test” then Find Evaluation 8734. Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.


Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), Sanofi, US, and Medtelligence, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, Sanofi, US, and Medtelligence, LLC. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.